Literature DB >> 9484961

Intramuscular artemether vs intravenous quinine: an open, randomized trial in Malawian children with cerebral malaria.

T E Taylor1, B A Wills, J M Courval, M E Molyneux.   

Abstract

OBJECTIVES: To compare artemether (by intramuscular injection) and quinine (by intravenous infusion) as treatments for cerebral malaria in African children.
METHODS: An open, randomized trial conducted at the Queen Elizabeth Central Hospital in Blantyre, Malawi. This trial was part of a multicentre study designed to determine if treatment with artemether would significantly lower mortality rates compared with quinine. Data from 83 artemether recipients and 81 quinine recipients are reported here.
RESULTS: Overall mortality rates and coma resolution times were not significantly different in the two treatment groups. Parasite and fever clearance times were significantly more rapid in the artemether recipients. Analyses which took into account the possible confounding variables did not significantly alter the findings of these unadjusted analyses.
CONCLUSION: These results do not suggest that treatment with artemether would confer a survival advantage in children with life-threatening malaria. The power and precision of the estimated treatment effects of artemether would be enhanced by a meta-analysis of all relevant clinical trials.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9484961     DOI: 10.1046/j.1365-3156.1998.00166.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  14 in total

Review 1.  Artemisinin derivatives versus quinine for cerebral malaria in African children: a systematic review.

Authors:  Hmwe Hmwe Kyu; Eduardo Fernández
Journal:  Bull World Health Organ       Date:  2009-07-30       Impact factor: 9.408

2.  Artemether for severe malaria.

Authors:  Ekpereonne B Esu; Emmanuel E Effa; Oko N Opie; Martin M Meremikwu
Journal:  Cochrane Database Syst Rev       Date:  2019-06-18

Review 3.  Artemisinin derivatives for treating severe malaria.

Authors:  H M McIntosh; P Olliaro
Journal:  Cochrane Database Syst Rev       Date:  2000

4.  Immune mimicry in malaria: Plasmodium falciparum secretes a functional histamine-releasing factor homolog in vitro and in vivo.

Authors:  S M MacDonald; J Bhisutthibhan; T A Shapiro; S J Rogerson; T E Taylor; M Tembo; J M Langdon; S R Meshnick
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-04       Impact factor: 11.205

Review 5.  Cerebral malaria: optimising management.

Authors:  Neema Mturi; Crispin O Musumba; Betty M Wamola; Bernhards R Ogutu; Charles R J C Newton
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

6.  Comparative efficacy and safety of the artemisinin derivatives compared to quinine for treating severe malaria in children and adults: A systematic update of literature and network meta-analysis.

Authors:  Nicholas Nyaaba; Nana Efua Andoh; Gordon Amoh; Dominic Selorm Yao Amuzu; Mary Ansong; José M Ordóñez-Mena; Jennifer Hirst
Journal:  PLoS One       Date:  2022-07-20       Impact factor: 3.752

7.  Randomized control trial of quinine and artesunate in complicated malaria.

Authors:  Anil Kumar Mohanty; B K Rath; R Mohanty; A K Samal; K Mishra
Journal:  Indian J Pediatr       Date:  2004-04       Impact factor: 1.967

Review 8.  Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria.

Authors:  Jane Achan; Ambrose O Talisuna; Annette Erhart; Adoke Yeka; James K Tibenderana; Frederick N Baliraine; Philip J Rosenthal; Umberto D'Alessandro
Journal:  Malar J       Date:  2011-05-24       Impact factor: 2.979

9.  Lack of decline in childhood malaria, Malawi, 2001-2010.

Authors:  Arantxa Roca-Feltrer; Collins J Kwizombe; Miguel A Sanjoaquin; Sanie S S Sesay; Brian Faragher; Jim Harrison; Karen Geukers; Storn Kabuluzi; Don P Mathanga; Elizabeth Molyneux; Maganizo Chagomera; Terrie Taylor; Malcolm Molyneux; Robert S Heyderman
Journal:  Emerg Infect Dis       Date:  2012-02       Impact factor: 6.883

10.  Intravenous artesunate for severe malaria in travelers, Europe.

Authors:  Thomas Zoller; Thomas Junghanss; Annette Kapaun; Ida Gjorup; Joachim Richter; Mats Hugo-Persson; Kristine Mørch; Behruz Foroutan; Norbert Suttorp; Salih Yürek; Holger Flick
Journal:  Emerg Infect Dis       Date:  2011-05       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.